SecBot SecBot
EFFECT ·Filed Jun 9, 2026

CGEN

COMPUGEN LTD
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC9999999995-26-001920
IPO/offering going effective
Actionable Insight • Neutral

Monitor for any subsequent prospectus supplement or takedown announcement, which would reveal the size and pricing of an actual offering. The shelf's effectiveness itself is a routine procedural step, but the overhang may weigh on the stock until the company signals its intentions.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.02
T+0 close · Jun 9, 2026 · via day close
Latest settled
+30.20%
T+60 · $2.63
Vs SPY
+26.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 9 $2.02entry
  2. T+1 · 5mo ago −2.97%α −1.39% · $1.96
  3. T+5 · 5mo ago 0.00%α −2.41% · $2.02
  4. T+20 · 4mo ago +18.32%α +16.87% · $2.39
  5. T+60 · 3mo ago +30.20%α +26.38% · $2.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Compugen's shelf registration statement on Form F-3 (File No. 333-295989) was declared effective by the SEC on June 8, 2026. This allows the company to offer and sell securities, including common shares, from time to time at its discretion, creating a potential dilution overhang for existing shareholders.

Key Facts

  • Shelf registration on Form F-3 (File No. 333-295989) declared effective on June 8, 2026.
  • Company can now offer and sell securities (e.g., common shares) at any time without further SEC review.
  • No specific offering size, pricing, or timing was disclosed in the effectiveness notice.

Financial Impact

No dollar amount disclosed; potential dilution from future offerings is indeterminate.

dilutionshare count

Risk Factors

  • Future share issuance could dilute existing holders.
  • Uncertainty about the timing and size of any offering may create overhang.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001920
Document: 9999999995-26-001920-index.html9999999995-26-001920
Document: 9999999995-26-001920.txt9999999995-26-001920

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026